4:46 PM
 | 
Oct 10, 2013
 |  BC Extra  |  Clinical News

Relypsa's patiromer meets in second part of hyperkalemia trial

Relypsa Inc. (Redwood City, Calif.) said twice-daily oral patiromer ( RLY5016) plus renin-angiotensin-aldosterone system (RAAS) inhibitor therapy met the primary endpoint in the second part of a two-part Phase III trial...

Read the full 143 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >